Expert Discusses Next Steps With T-VEC in Melanoma
Howard L. Kaufman, MD, discusses remaining questions regarding T-VEC, the impact of the FDA approval, and its future potential.
ASCO Guideline Clarifies Biomarker Assay Use in Adjuvant Breast Cancer Care
ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.
Nivolumab Hailed as “Game Changer” in Head and Neck Cancer
Robert Ferris, MD, PhD, discusses CheckMate-141, the biggest remaining challenges in head and neck cancer, and the potential for nivolumab as a treatment of patients with the disease.
Liver-Directed Therapy for Hepatic Malignancies
Management of hepatic malignancies requires a multidisciplinary approach, and is based on the tumor burden, liver function, and PS of the patient.
Oncologists Must Take Lead Role in Developing Clinical Pathways
Pathways are effective tools for reducing unnecessary variability in care, a key factor in achieving better outcomes and more predictable costs.
Patient-Derived Xenografts Could Improve Precision Medicine Outcomes
Researchers at the UC Davis Comprehensive Cancer Center are working to make personalized treatment more precise using tumor xenografts in mice to test and identify more precise treatments for bladder cancer. patients.
FDA Grants Antibody-Drug Conjugate Breakthrough Designation in TNBC
Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.